Program
penpulimab
Also written as “AK105”, “Penpulimab” and “Penpulimab injection”.
Its studies are mostly in Carcinoma, Hepatocellular · Nasopharyngeal Carcinoma · Carcinoma, Non-Small-Cell Lung · Hodgkin Disease · Esophageal Squamous Cell Carcinoma, led by 2 companies.
Drug pagePenpulimab: every studyAll 65 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sino Biopharmaceutical | 187 open or running | phase 3since Apr 10, 2020 | Dec 17, 2019 | Dec 2026phase 3 · NCT04344158 |
| Akesoits history only | 92 open or running | phase 3since Mar 6, 2019 | Nov 21, 2017 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Sino Biopharmaceutical only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Before these, 3 studies since Dec 17, 2019.
- Apr 10, 2020Phase 3 study in Advanced Hepatocellular Carcinoma (HCC)NCT04344158 · 648 enrolled · China
- May 9, 2020Phase 3 study in Advanced Gastric and Gastro-oesophageal Junction AdenocarcinomaNCT04385550 · 528 enrolled · China
- Jun 9, 2020Named penpulimabINNProposed as its International Nonproprietary Name in WHO's List 123 · before, AK105
- Sep 24, 2021Phase 2 study in Unresectable Metastatic Colorectal CancerNCT05068206 · 120 enrolled · China
- Apr 12, 2022Phase 1 study in Advanced CancersNCT05333276 · 7 enrolled · China
- May 16, 2022Phase 2 study in LymphomaNCT05400876 · 92 enrolled · China
- Sep 27, 2022Phase 2 study in Nasopharyngeal CarcinomaNCT05563480 · 47 enrolled · China
- Apr 18, 2023Phase 2 study in Advanced Esophageal Squamous Cell CarcinomaNCT05834543 · 34 enrolled · China
- May 15, 2023Phase 3 study in Carcinoma, HepatocellularNCT05862337 · 480 planned · China
- May 31, 2023Phase 1 study in Advanced CancerNCT05894421 · 92 planned · China
- Jul 27, 2023Phase 1 study in Advanced Hepatocellular CarcinomaNCT05975645 · 29 enrolled · China
- Mar 1, 20242 phase 1 studiesNCT06297642, NCT06320080
- Jul 8, 2024Phase 2 study in SarcomaNCT06500091 · 54 planned · China
- Jan 6, 2025Phase 2 study in Gastroesophageal AdenocarcinomaNCT06767800 · 204 planned · China
- Feb 9, 2025Phase 2 study in Advanced Solid TumorNCT06825494 · 194 planned · China
Ahead
- Dec 2026Primary completion: phase 3 study in Advanced Hepatocellular Carcinoma (HCC)NCT04344158
TargetBeta
“A monoclonal antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), ”NCIt, by rule
“Programmed cell death protein 1 inhibitor”ChEMBL 37, by rule
Other programs on PDCD1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ivonescimabrule | Akeso | phase 3 | 48 |
| rilvegostomig | AstraZeneca | phase 3 | 24 |
| Iparomlimab/Tuvonralimabrule | Qilu Pharmaceutical | phase 3 | 22 |
| volrustomig | AstraZeneca | phase 3 | 19 |
| tivunatamig | Pfizer | phase 3 | 15 |
| nilvanstomigrule | Suzhou Zelgen Biopharmaceuticals | phase 3 | 15 |
| pucotenlimabrule | taizhou-hanzhong-biomedical-co-ltd | phase 3 | 15 |
| enlonstobartrule | CSPC Pharmaceutical Group | phase 3 | 15 |
| ezabenlimab | Boehringer Ingelheim | phase 3 | 13 |
| Anti-PD-1/IL-2 Bispecific Antibody Fusion Protein IBI363rule | Innovent Biologics | phase 3 | 10 |
| rulonilimabrule | Lunan Pharmaceutical Group | phase 3 | 9 |
| Anti-PD-1/Anti-TGF-beta Bifunctional Fusion Protein TQB2868 | Sino Biopharmaceutical | phase 3 | 4 |
Studies
All 18 Sino Biopharmaceutical leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06825494Advanced Solid Tumor · China | 2 | Recruiting | Mar 2026 | 194 |
| NCT06767800Gastroesophageal Adenocarcinoma · China | 2 | Recruiting | Sep 2026 | 204 |
| NCT06500091Sarcoma · China | 2 | Not yet recruiting | Jun 2026 | 54 |
| NCT06320080Advanced Hepatocellular Carcinoma · China | 1 | Terminated | Nov 3, 2025 | 22 |
| NCT06297642Advanced Malignant Neoplasm · China | 1 | Terminated | Jul 31, 2024 | 3 |
| NCT05975645Advanced Hepatocellular Carcinoma · China | 1 | Terminated | Jun 4, 2025 | 29 |
| NCT05894421Advanced Cancer · China | 1 | Recruiting | Jan 2025 | 92 |
| NCT05862337Carcinoma, Hepatocellular · China | 3 | Recruiting | Aug 2024 | 480 |
| NCT05834543Advanced Esophageal Squamous Cell Carcinoma · China | 2 | Terminated | Oct 23, 2024 | 34 |
| NCT05563480Nasopharyngeal Carcinoma · China | 2 | Completed | May 28, 2025 | 47 |
| NCT05400876Lymphoma · China | 2 | UNKNOWN | May 2023 | 92 |
| NCT05333276Advanced Cancers · China | 1 | Active, not recruiting | Dec 2023 | 7 |
| NCT05068206Unresectable Metastatic Colorectal Cancer · China | 2 | UNKNOWN | Dec 2023 | 120 |
| NCT04385550Advanced Gastric and Gastro-oesophageal Junction Adenocarcinoma · China | 3 | UNKNOWN | Oct 31, 2023 | 528 |
| NCT04344158Advanced Hepatocellular Carcinoma (HCC) · China | 3 | Active, not recruiting | Dec 2026 | 648 |
| NCT04291248MSI-H or dMMR Advanced Solid Tumors · China | 2 | UNKNOWN | Dec 2022 | 138 |
| NCT04207463Digestive System Neoplasms · China | 2 | UNKNOWN | Dec 31, 2020 | 150 |
| NCT04203719Advanced Head, Neck and Chest Cancer · China | 2 | UNKNOWN | Dec 31, 2020 | 140 |
How it is read
Names in the registry
- “AK105”, 9 entries
- “Penpulimab”, 3 entries
- “Penpulimab injection”, 2 entries
- “AK105 injection”, 2 entries
- “TQB2618 injection; Penpulimab injection”, 1 entry
Conditions, from the studies’ own filings
- Carcinoma, Hepatocellular, 5 studies
- Nasopharyngeal Carcinoma, 3 studies
- Carcinoma, Non-Small-Cell Lung, 2 studies
- Hodgkin Disease, 2 studies
- Esophageal Squamous Cell Carcinoma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.